Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease.

Recent progress in molecular biology has provided new techniques for inhibiting target gene expression. In particular, the application of DNA technology, such as antisense strategy to regulate the transcription of disease-related genes in vivo, has important therapeutic potential. Recently, transfection of cis-element double-stranded oligodeoxynucleotides (ODNs), referred to as "decoy" ODNs, has been reported to be a powerful tool in a new class of anti-gene strategies for gene therapy and in the study of transcriptional regulation. Transfection of double-stranded ODNs corresponding to the cis sequence will result in the attenuation of authentic cis-trans interaction, leading to the removal of trans factors from the endogenous cis elements with subsequent modulation of gene expression. This "decoy" strategy is not only a novel strategy for gene therapy as an anti-gene strategy but also a powerful tool for the study of endogenous gene regulation in vivo as well as in vitro. In this article, we reviewed (1) the mechanisms and (2) the potential applications of decoy strategy.

[1]  C. Stein,et al.  Oligodeoxynucleotides as inhibitors of gene expression: a review. , 1988, Cancer research.

[2]  D. Baltimore,et al.  NF-κB: A pleiotropic mediator of inducible and tissue-specific gene control , 1989, Cell.

[3]  M. Reidy,et al.  Regulation of Smooth Muscle Cell Growth in Injured Artery , 1989, Journal of cardiovascular pharmacology.

[4]  K. Iwai,et al.  Increased expression of DNA cointroduced with nuclear protein in adult rat liver. , 1989, Science.

[5]  T. Libermann,et al.  Activation of interleukin-6 gene expression through the NF-kappa B transcription factor , 1990, Molecular and cellular biology.

[6]  D. Brennan,et al.  Mesangial cell accessory functions: mediation by intercellular adhesion molecule-1. , 1990, Kidney international.

[7]  S. Takahashi,et al.  Structure and expression of the human angiotensinogen gene. Identification of a unique and highly active promoter. , 1990, The Journal of biological chemistry.

[8]  Eli Gilboa,et al.  Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication , 1990, Cell.

[9]  G. Nabel,et al.  Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. , 1990, Science.

[10]  L. Orgel,et al.  The stability of different forms of double-stranded decoy DNA in serum and nuclear extracts. , 1992, Nucleic acids research.

[11]  S. Weintraub,et al.  Retinoblastoma protein switches the E2F site from positive to negative element , 1992, Nature.

[12]  Amyj . Williams,et al.  Functional analysis of the human vascular cell adhesion molecule 1 promoter , 1992, The Journal of experimental medicine.

[13]  D Schwartz,et al.  A Cascade Model for Restenosis: A Special Case of Atherosclerosis Progression , 1992, Circulation.

[14]  J. Chow,et al.  ICAM-1 expression in renal disease. , 1992, Journal of clinical pathology.

[15]  M. Pagano,et al.  Association of cdk2 kinase with the transcription factor E2F during S phase. , 1992, Science.

[16]  T. Ogihara,et al.  Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Larry J. Smith,et al.  Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey , 1993 .

[18]  T. Collins.  Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[19]  E. Schulze-Lohoff,et al.  Cytokines and mesangial cells. , 1993, Kidney international. Supplement.

[20]  A. Ortiz,et al.  Role of tumor necrosis factor-alpha in the pathogenesis of glomerular diseases. , 1993, Kidney international. Supplement.

[21]  J. Sedor,et al.  Cytokines, mesangial cell activation and glomerular injury. , 1993, Kidney international. Supplement.

[22]  J. Floege,et al.  Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. , 1993, Kidney international. Supplement.

[23]  C. Malvy,et al.  Sequence-specific interaction of α β-anomeric doublestranded DNA with the p50 subunit of NFxB: application to the decoy approach , 1994 .

[24]  J. Satriano,et al.  Activation and attenuation of transcription factor NF-kB in mouse glomerular mesangial cells in response to tumor necrosis factor-alpha, immunoglobulin G, and adenosine 3':5'-cyclic monophosphate. Evidence for involvement of reactive oxygen species. , 1994, The Journal of clinical investigation.

[25]  G. Gibbons,et al.  The emerging concept of vascular remodeling. , 1994, The New England journal of medicine.

[26]  A. Fukamizu,et al.  Molecular mechanism of transcriptional activation of angiotensinogen gene by proximal promoter. , 1994, The Journal of clinical investigation.

[27]  T. Ogihara,et al.  Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. , 1994, Gene.

[28]  M. Entman,et al.  Adhesion Molecule-Dependent Cardiovascular Injury , 1994 .

[29]  T. Ogihara,et al.  Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. , 1994, The Journal of clinical investigation.

[30]  M. Blumenfeld,et al.  Inhibition of HSV-1 proliferation by decoy phosphodiester oligonucleotides containing ICP4 recognition sequences. , 1995, Gene expression.

[31]  S. Wesselingh,et al.  Cytokine mRNA expression in postischemic/reperfused myocardium. , 1995, The American journal of pathology.

[32]  S. Crooke.  Progress in antisense therapeutics. , 1996, Hematologic pathology.

[33]  S. Ross,et al.  The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Aoki,et al.  Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. , 1995, Hypertension.

[35]  E. Gilboa,et al.  Inhibition of HIV-1 in CEM cells by a potent TAR decoy. , 1995, Gene therapy.

[36]  S. Srinivasan,et al.  Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides , 1995, Journal of clinical laboratory analysis.

[37]  M. Entman,et al.  Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. , 1995, The Journal of clinical investigation.

[38]  R. Morishita,et al.  In vivo identification of a negative regulatory element in the mouse renin gene using direct gene transfer. , 1995, The Journal of clinical investigation.

[39]  M. Giacca,et al.  Molecular and functional interactions of transcription factor USF with the long terminal repeat of human immunodeficiency virus type 1 , 1995, Journal of virology.

[40]  M. Aoki,et al.  Effect of angiotensinogen on blood pressure regulation in normotensive rats: application of a loss of function approach , 1995, Journal of hypertension.

[41]  A. J. Lusis,et al.  Pathogenesis of Atherosclerosis , 1964, The American journal of cardiology.

[42]  T. Ogihara,et al.  A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[43]  L. Benimetskaya,et al.  Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. , 1996, Nucleic acids research.

[44]  H. W. Sharma,et al.  The NF-kappaB transcription factor in oncogenesis. , 1996, Anticancer research.

[45]  D S Latchman,et al.  Transcription-factor mutations and disease. , 1996, The New England journal of medicine.

[46]  M. Horiuchi,et al.  In vivo gene transfer and gene modulation in hypertension research. , 1996, Hypertension.

[47]  H. W. Sharma,et al.  Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis. , 1996, Anticancer research.

[48]  M. Aoki,et al.  Role of transcriptional cis-elements, angiotensinogen gene-activating elements, of angiotensinogen gene in blood pressure regulation. , 1996, Hypertension.

[49]  D. Kohn,et al.  Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture , 1996, Journal of virology.

[50]  J. Jackson,et al.  Manipulation of Distinct NFκB Proteins Alters Interleukin-1β-induced Human Rheumatoid Synovial Fibroblast Prostaglandin E2 Formation* , 1996, The Journal of Biological Chemistry.

[51]  M. Stella,et al.  Ets up-regulates MET transcription. , 1996, Oncogene.

[52]  R. Knuechel,et al.  Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. , 1996, The Journal of clinical investigation.

[53]  Y. Kaneda,et al.  A novel strategy for myocardial protection using in vivo transfection of cis element 'decoy' against NFkappaB binding site: evidence for a role of NFkappaB in ischemia-reperfusion injury. , 1997, Circulation.

[54]  D. Kornbrust,et al.  Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. , 1997, Toxicology.

[55]  Y. Kaneda,et al.  A novel strategy for myocardial protection using in vivo transfection of cis element 'decoy' against NFkB binding site : Evidence for a role of NFkB in ischemia-reperfusion injury. Commentary , 1997 .

[56]  T. Ogihara,et al.  In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction , 1997, Nature Medicine.

[57]  M. Runge,et al.  Hypoxia Induces Cyclooxygenase-2 via the NF-κB p65 Transcription Factor in Human Vascular Endothelial Cells* , 1997, The Journal of Biological Chemistry.

[58]  J. Isner.  Oligonucleotide therapeutics — Novel cardiovascular targets , 1997, Nature Medicine.

[59]  M. Pangburn,et al.  Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. , 1997, The Journal of pharmacology and experimental therapeutics.